Health Canada Approves Merck's Keytruda With Enfortumab Vedotin For Bladder Cancer
rttnews·- Health Canada approved Merck's Keytruda combined with enfortumab vedotin for treating specific adult muscle-invasive bladder cancer patients. - The approval applies to patients ineligible for cisplatin-containing chemotherapy for use as neoadjuvant and adjuvant treatments around surgery. - This regulatory decision is supported by Phase 3 KEYNOTE-905 trial data demonstrating significant survival improvements over surgery alone.